Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-microRNA-23b-3p
- Development stage
- Preclinical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
anti-microRNA-23b-3p is an antisense oligonucleotide (ASO) designed to specifically target and neutralize microRNA-23b-3p (miR-23b-3p). In hepatocellular carcinoma (HCC), miR-23b-3p is known to promote resistance to sorafenib by modulating cytoprotective autophagy and glutamine metabolism (glutamine addiction). By sequestering miR-23b-3p through complementary base pairing, this anti-miRNA agent prevents the miRNA from silencing its target messenger RNAs, thereby inhibiting the survival mechanisms that allow cancer cells to evade treatment. It is currently utilized in preclinical research to explore miRNA-based therapeutic strategies for overcoming drug resistance and metabolic reprogramming in oncology.
- Other names
- miR-23b-3p antagomirmiR23b-3p antagomirmiR 23b-3p antagomirantisense miR-23b-3p
Beyond the preview
Go deeper on anti-microRNA-23b-3p.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-microRNA-23b-3p.